Verona Pharma appoints Dr Ken Cunningham and Dr Anders Ullman as Non-Executive Directors

11-Sep-2015 - Verona Pharma plc announced the appointment of Ken Cunningham, MD and Anders Ullman, MD, PhD, as Non-Executive Directors of the Company with effect from 10 September 2015. Dr Cunningham will replace Professor Jones as the Non-Executive Director appointed by the Wales Life Sciences Investment Fund ...

US Patent Granted for Verona Pharma’s RPL554

29-Aug-2012 - Verona Pharma plc announced that the United States Patent and Trademark Office has granted a new patent for the Company’s lead drug candidate, RPL554. The patent is the fourth patent issued for RPL554 and related compounds in the US.RPL554, Verona Pharma's lead drug candidate, is a dual ...

Verona Pharma Appoints New CEO

03-May-2012 - Verona Pharma plc announced the appointment of Dr Sven Jan-Anders Karlsson (aged 57) as Chief Executive Officer with effect from 1 June 2012. Dr Karlsson has broad pharmaceutical and biotechnology R&D and corporate experience. He was formerly the CEO at S*BIO, a Singapore and US based ...

Verona Pharma appoints Manchester clinical research facility to carry out first UK-based anti-inflammatory clinical trial with RPL554

12-Mar-2012 - Verona Pharma plc has signed a contract with the Medicines Evaluation Unit (MEU) in Manchester, UK to undertake a Phase II clinical trial to demonstrate the anti-inflammatory effects of RPL554 with respect to chronic obstructive pulmonary disease (COPD). The trial, being led by Professor Dave ...

Verona Pharma's phase IIa RPL554 study reports positively for safety and bronchodilation in patients with mild to moderate COPD

Successful pilot study to drive future COPD trials

15-Nov-2011 - Verona Pharma plc has successfully demonstrated in a Phase IIa RPL554 study bronchodilator effects in patients with chronic obstructive pulmonary disease (“COPD”).The pilot Phase IIa study was carried out by a world leading expert on COPD, Professor Mario Cazzola at the Tor Vergata Polyclinic, ...

Verona Pharma commences new Phase II Clinical Trial of RPL554 in Asthma

First patient treated in repeat dosing trial in the Netherlands

17-May-2011 - Verona Pharma plc has commenced a new trial with its lead respiratory drug, RPL554, at the Centre for Human Drug Research (“CHDR”) in the Netherlands.Verona has treated its first patient in this Phase II clinical trial which is designed to determine whether RPL554 has sustained bronchodilator ...

Verona's first COPD Trial with RPL554 begins in Rome

14-Apr-2011 - Verona Pharma plc has commenced a new trial with its lead respiratory drug, RPL554, in patients with chronic obstructive pulmonary disease (COPD).This Phase II trial is taking place at University of Tor Vergata in Rome, and is designed to evaluate the safety and efficacy of RPL554 in patients ...

Verona Pharma announces positive results for RPL554 in mild asthma at higher doses

22-Feb-2011 - Verona Pharma plc has completed a successful trial of higher doses of its lead respiratory drug, RPL554, in patients with mild asthma. The randomised, blinded trial, with placebo control, took place in Leiden, The Netherlands, at the Centre for Human Drug Research (CHDR). The trial treated a ...

Verona Pharma applies for approval to test RPL554 in UK clinical trials

04-Feb-2011 - Verona Pharma plc has applied to the Medicines and Healthcare Products Regulatory Agency (MHRA), the Governmental agency in the UK with responsibility for standards of safety, quality and performance of new drug treatments, to conduct clinical trials in the UK.RPL554 is Verona Pharma’s lead drug ...

Verona Pharma commences clinical trial of VRP700 for chronic cough

28-Oct-2010 - Verona Pharma plc has initiated its clinical trial of VRP700, an innovative treatment for chronic cough, in Florence, Italy, with the treatment of the first patient. The trial is expected to be completed during the first quarter of 2011, depending on patient recruitment and the efficacy of the ...